Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Fairfax, VA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Newport News, VA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Spokane, WA
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Green Bay, WI
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
mi
from
Albury,
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
mi
from
Albury,
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Tucson, AZ
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated:  2/14/2018
Clinical Research Facility
mi
from
Bismarck, ND
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Status: Enrolling
Updated: 2/14/2018
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
Mayo Clinic Hospital
mi
from
Scottsdale, AZ
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
Mayo Clinic Hospital
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
University of Florida
mi
from
Gainesville, FL
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
University of Chicago
mi
from
Chicago, IL
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated:  2/14/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Status: Enrolling
Updated: 2/14/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated:  2/16/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated: 2/16/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated:  2/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated: 2/16/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated:  2/16/2018
University of Washington Medical Center
mi
from
Seattle, WA
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated: 2/16/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated:  2/16/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status: Enrolling
Updated: 2/16/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/19/2018
Urology Cancer Center, PC
mi
from
Omaha, NE
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/19/2018
Urology Cancer Center, PC
mi
from
Omaha, NE
Click here to add this to my saved trials
Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery
A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer
Status: Enrolling
Updated:  2/19/2018
City of Hope Medical Center
mi
from
Duarte, CA
Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery
A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer
Status: Enrolling
Updated: 2/19/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Pilot Study of Eovist (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer
Status: Enrolling
Updated:  2/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Pilot Study of Eovist (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer
Status: Enrolling
Updated: 2/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study
Status: Enrolling
Updated:  2/20/2018
Stanford University School of Medicine
mi
from
Palo Alto, CA
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study
Status: Enrolling
Updated: 2/20/2018
Stanford University School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
University of California at San Francisco
mi
from
San Francisco, CA
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Scottsdale Healthcare Hospitals DBA HonorHealth
mi
from
Scottsdale, AZ
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Scottsdale Healthcare Hospitals DBA HonorHealth
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
British Columbia Cancer Agency - Vancouver Centre
mi
from
Vancouver,
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
British Columbia Cancer Agency - Vancouver Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Oral Calcitriol With Ketoconazole in CRPC
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
Status: Enrolling
Updated:  2/28/2018
Inova Schar Cancer Institute
mi
from
Fairfax, VA
Oral Calcitriol With Ketoconazole in CRPC
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone
Status: Enrolling
Updated: 2/28/2018
Inova Schar Cancer Institute
mi
from
Fairfax, VA
Click here to add this to my saved trials
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated:  3/2/2018
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated: 3/2/2018
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated:  3/2/2018
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
mi
from
Pittsburgh, PA
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated: 3/2/2018
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated:  3/2/2018
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
mi
from
Saint Louis, MO
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated: 3/2/2018
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated:  3/2/2018
Louis Stokes VA Medical Center, Cleveland, OH
mi
from
Cleveland, OH
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Status: Enrolling
Updated: 3/2/2018
Louis Stokes VA Medical Center, Cleveland, OH
mi
from
Cleveland, OH
Click here to add this to my saved trials
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated:  3/5/2018
Fox Chase Cancer Center - Cheltenham
mi
from
Philadelphia, PA
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated: 3/5/2018
Fox Chase Cancer Center - Cheltenham
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated:  3/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners
A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners
Status: Enrolling
Updated: 3/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated:  3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI
Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning
Status: Enrolling
Updated: 3/6/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
UCLA Medical Center, Clark Urology Center
mi
from
Los Angeles, CA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
UCLA Medical Center, Clark Urology Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
mi
from
Philadelphia, PA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/6/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/6/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated:  3/7/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation
Status: Enrolling
Updated: 3/7/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/8/2018
Georgetown University Medical Center
mi
from
Washington,
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/8/2018
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/8/2018
Providence Portland Medical Center
mi
from
Portland, OR
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/8/2018
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Status: Enrolling
Updated:  3/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Status: Enrolling
Updated: 3/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Hematology Oncology Associates
mi
from
Phoenix, AZ
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Advanced Medical Specialties
mi
from
Miami, FL
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Advanced Medical Specialties
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Ocala Oncology Center
mi
from
Ocala, FL
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  3/9/2018
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 3/9/2018
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
Click here to add this to my saved trials